nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—TNF—Graves' disease	0.743	1	CbGaD
Pomalidomide—CYP1A2—Methimazole—Graves' disease	0.132	0.656	CbGbCtD
Pomalidomide—CYP3A4—Methimazole—Graves' disease	0.0693	0.344	CbGbCtD
Pomalidomide—Thalidomide—TNF—Graves' disease	0.00358	1	CrCbGaD
Pomalidomide—Interstitial lung disease—Propylthiouracil—Graves' disease	0.00292	0.139	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Methimazole—Graves' disease	0.00133	0.0634	CcSEcCtD
Pomalidomide—TNF—Death Receptor Signalling—FASLG—Graves' disease	0.00114	0.037	CbGpPWpGaD
Pomalidomide—Neuropathy peripheral—Propylthiouracil—Graves' disease	0.00113	0.0539	CcSEcCtD
Pomalidomide—TNF—Death Receptor Signalling—FAS—Graves' disease	0.0011	0.0357	CbGpPWpGaD
Pomalidomide—Vertigo—Methimazole—Graves' disease	0.000953	0.0454	CcSEcCtD
Pomalidomide—Leukopenia—Methimazole—Graves' disease	0.00095	0.0452	CcSEcCtD
Pomalidomide—TNF—Apoptosis—TNFRSF25—Graves' disease	0.000922	0.0299	CbGpPWpGaD
Pomalidomide—Arthralgia—Methimazole—Graves' disease	0.000903	0.043	CcSEcCtD
Pomalidomide—Thrombocytopenia—Methimazole—Graves' disease	0.000848	0.0404	CcSEcCtD
Pomalidomide—Vertigo—Propylthiouracil—Graves' disease	0.000811	0.0386	CcSEcCtD
Pomalidomide—Leukopenia—Propylthiouracil—Graves' disease	0.000808	0.0385	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Methimazole—Graves' disease	0.000789	0.0376	CcSEcCtD
Pomalidomide—Arthralgia—Propylthiouracil—Graves' disease	0.000768	0.0366	CcSEcCtD
Pomalidomide—Thrombocytopenia—Propylthiouracil—Graves' disease	0.000721	0.0343	CcSEcCtD
Pomalidomide—Body temperature increased—Methimazole—Graves' disease	0.000685	0.0326	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Propylthiouracil—Graves' disease	0.000671	0.032	CcSEcCtD
Pomalidomide—Pruritus—Methimazole—Graves' disease	0.000613	0.0292	CcSEcCtD
Pomalidomide—TNF—Cytokines and Inflammatory Response—HLA-DRB1—Graves' disease	0.000586	0.019	CbGpPWpGaD
Pomalidomide—Body temperature increased—Propylthiouracil—Graves' disease	0.000582	0.0277	CcSEcCtD
Pomalidomide—TNF—HIV-1 Nef: Negative effector of Fas and TNF-alpha—FASLG—Graves' disease	0.000576	0.0187	CbGpPWpGaD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CTLA4—Graves' disease	0.000572	0.0185	CbGpPWpGaD
Pomalidomide—TNF—HIV-1 Nef: Negative effector of Fas and TNF-alpha—FAS—Graves' disease	0.000556	0.018	CbGpPWpGaD
Pomalidomide—Vomiting—Methimazole—Graves' disease	0.000551	0.0262	CcSEcCtD
Pomalidomide—Rash—Methimazole—Graves' disease	0.000546	0.026	CcSEcCtD
Pomalidomide—Dermatitis—Methimazole—Graves' disease	0.000546	0.026	CcSEcCtD
Pomalidomide—Headache—Methimazole—Graves' disease	0.000543	0.0258	CcSEcCtD
Pomalidomide—Pruritus—Propylthiouracil—Graves' disease	0.000521	0.0248	CcSEcCtD
Pomalidomide—Nausea—Methimazole—Graves' disease	0.000514	0.0245	CcSEcCtD
Pomalidomide—TNF—amb2 Integrin signaling—ICAM1—Graves' disease	0.000491	0.0159	CbGpPWpGaD
Pomalidomide—TNF—FAS pathway and Stress induction of HSP regulation—FASLG—Graves' disease	0.000475	0.0154	CbGpPWpGaD
Pomalidomide—Vomiting—Propylthiouracil—Graves' disease	0.000468	0.0223	CcSEcCtD
Pomalidomide—Rash—Propylthiouracil—Graves' disease	0.000464	0.0221	CcSEcCtD
Pomalidomide—Dermatitis—Propylthiouracil—Graves' disease	0.000464	0.0221	CcSEcCtD
Pomalidomide—Headache—Propylthiouracil—Graves' disease	0.000461	0.022	CcSEcCtD
Pomalidomide—TNF—FAS pathway and Stress induction of HSP regulation—FAS—Graves' disease	0.000458	0.0148	CbGpPWpGaD
Pomalidomide—TNF—Cellular roles of Anthrax toxin—IL1B—Graves' disease	0.00045	0.0146	CbGpPWpGaD
Pomalidomide—TNF—IL27-mediated signaling events—IFNG—Graves' disease	0.000441	0.0143	CbGpPWpGaD
Pomalidomide—Nausea—Propylthiouracil—Graves' disease	0.000437	0.0208	CcSEcCtD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IFNG—Graves' disease	0.000428	0.0139	CbGpPWpGaD
Pomalidomide—TNF—Cytokines and Inflammatory Response—CD4—Graves' disease	0.000413	0.0134	CbGpPWpGaD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FASLG—Graves' disease	0.000413	0.0134	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—HLA-E—Graves' disease	0.000412	0.0133	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—CD40—Graves' disease	0.000402	0.013	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—CTLA4—Graves' disease	0.000396	0.0128	CbGpPWpGaD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2RA—Graves' disease	0.000396	0.0128	CbGpPWpGaD
Pomalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—FASLG—Graves' disease	0.000395	0.0128	CbGpPWpGaD
Pomalidomide—TNF—IL27-mediated signaling events—IL1B—Graves' disease	0.000393	0.0127	CbGpPWpGaD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IL1B—Graves' disease	0.000382	0.0124	CbGpPWpGaD
Pomalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2RA—Graves' disease	0.000379	0.0123	CbGpPWpGaD
Pomalidomide—TNF—Caspase Cascade in Apoptosis—FASLG—Graves' disease	0.000372	0.012	CbGpPWpGaD
Pomalidomide—TNF—Caspase Cascade in Apoptosis—FAS—Graves' disease	0.000359	0.0116	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CTLA4—Graves' disease	0.000354	0.0114	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—CD8A—Graves' disease	0.000352	0.0114	CbGpPWpGaD
Pomalidomide—TNF—Vitamin B12 Metabolism—ICAM1—Graves' disease	0.000338	0.0109	CbGpPWpGaD
Pomalidomide—TNF—Monoamine Transport—IL1B—Graves' disease	0.000333	0.0108	CbGpPWpGaD
Pomalidomide—TNF—IL23-mediated signaling events—IFNG—Graves' disease	0.000333	0.0108	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—FASLG—Graves' disease	0.000331	0.0107	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—CD40—Graves' disease	0.000328	0.0106	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—HLA-DQB1—Graves' disease	0.000326	0.0106	CbGpPWpGaD
Pomalidomide—TNF—IL23-mediated signaling events—CD4—Graves' disease	0.000321	0.0104	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—IL2RA—Graves' disease	0.000317	0.0103	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—HLA-A—Graves' disease	0.000314	0.0102	CbGpPWpGaD
Pomalidomide—TNF—IL23-mediated signaling events—IL1B—Graves' disease	0.000297	0.0096	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—HLA-B—Graves' disease	0.000293	0.00949	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—CXCL10—Graves' disease	0.000293	0.00949	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—FASLG—Graves' disease	0.000287	0.00928	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—IFNG—Graves' disease	0.000279	0.00904	CbGpPWpGaD
Pomalidomide—TNF—Alzheimers Disease—FAS—Graves' disease	0.000276	0.00895	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—FAS—Graves' disease	0.000276	0.00895	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—ICAM1—Graves' disease	0.000275	0.0089	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—IL2RA—Graves' disease	0.000275	0.00889	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—FASLG—Graves' disease	0.000273	0.00883	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—HLA-A—Graves' disease	0.000272	0.00879	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—FAS—Graves' disease	0.000263	0.00852	CbGpPWpGaD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—Graves' disease	0.000261	0.00846	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—CXCL10—Graves' disease	0.000261	0.00844	CbGpPWpGaD
Pomalidomide—TNF—Vitamin B12 Metabolism—IFNG—Graves' disease	0.000257	0.00833	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—CD40—Graves' disease	0.000256	0.00829	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FASLG—Graves' disease	0.000256	0.00827	CbGpPWpGaD
Pomalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—Graves' disease	0.00025	0.00809	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—IL1B—Graves' disease	0.000249	0.00807	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—HLA-DRB1—Graves' disease	0.000248	0.00803	CbGpPWpGaD
Pomalidomide—TNF—TGF-beta Receptor Signaling—IFNG—Graves' disease	0.000246	0.00796	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2RA—Graves' disease	0.000245	0.00793	CbGpPWpGaD
Pomalidomide—TNF—Vitamin B12 Metabolism—IL1B—Graves' disease	0.000229	0.00743	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—CXCL10—Graves' disease	0.000229	0.00741	CbGpPWpGaD
Pomalidomide—PTGS2—Overview of nanoparticle effects—TNF—Graves' disease	0.000227	0.00734	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—ICAM1—Graves' disease	0.000219	0.00707	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—IFNG—Graves' disease	0.000209	0.00678	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—IFNG—Graves' disease	0.000209	0.00678	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—IL1B—Graves' disease	0.000187	0.00604	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—FAS—Graves' disease	0.000186	0.00601	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—IFNG—Graves' disease	0.000181	0.00587	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—HLA-E—Graves' disease	0.00018	0.00584	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—CD40—Graves' disease	0.000176	0.00571	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—CTLA4—Graves' disease	0.000174	0.00563	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—ICAM1—Graves' disease	0.000173	0.00559	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—FASLG—Graves' disease	0.000167	0.00541	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—IFNG—Graves' disease	0.000166	0.00538	CbGpPWpGaD
Pomalidomide—TNF—Alzheimers Disease—IL1B—Graves' disease	0.000162	0.00523	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—IL1B—Graves' disease	0.000162	0.00523	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—Graves' disease	0.000162	0.00523	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CXCL10—Graves' disease	0.000161	0.00522	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—FAS—Graves' disease	0.000161	0.00522	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—FASLG—Graves' disease	0.000157	0.00507	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—FAS—Graves' disease	0.000151	0.00489	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—IL1B—Graves' disease	0.000148	0.0048	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—HLA-DQB1—Graves' disease	0.000143	0.00463	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	0.000141	0.00458	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	0.000136	0.00441	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—ICAM1—Graves' disease	0.000135	0.00437	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—IL1B—Graves' disease	0.000132	0.00427	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—IFNG—Graves' disease	0.000132	0.00426	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—HLA-B—Graves' disease	0.000129	0.00416	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—FASLG—Graves' disease	0.000126	0.00407	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—FAS—Graves' disease	0.000121	0.00392	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL2RA—Graves' disease	0.00012	0.0039	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—HLA-A—Graves' disease	0.000119	0.00386	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—IL1B—Graves' disease	0.000117	0.0038	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.000113	0.00365	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—Graves' disease	0.000112	0.00362	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—HLA-DRB1—Graves' disease	0.000109	0.00352	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—ICAM1—Graves' disease	0.000107	0.00346	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—Graves' disease	0.000105	0.00339	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—CD4—Graves' disease	0.000103	0.00334	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—IL1B—Graves' disease	0.000103	0.00333	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—IFNG—Graves' disease	0.000103	0.00333	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—Graves' disease	9.78e-05	0.00317	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL1B—Graves' disease	9.38e-05	0.00304	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—IL1B—Graves' disease	9.17e-05	0.00297	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—IL1B—Graves' disease	8.84e-05	0.00286	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	8.75e-05	0.00283	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—Graves' disease	8.72e-05	0.00282	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	8.43e-05	0.00273	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IFNG—Graves' disease	8.13e-05	0.00263	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IFNG—Graves' disease	7.95e-05	0.00257	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IL1B—Graves' disease	7.25e-05	0.00235	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL1B—Graves' disease	7.09e-05	0.00229	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—GABRA3—Graves' disease	7.08e-05	0.00229	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—TNF—Graves' disease	6.66e-05	0.00215	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—GC—Graves' disease	6.39e-05	0.00207	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—Graves' disease	6.33e-05	0.00205	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—Graves' disease	6.33e-05	0.00205	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	6.2e-05	0.00201	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	5.98e-05	0.00194	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TNF—Graves' disease	5.26e-05	0.0017	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—TNF—Graves' disease	5.14e-05	0.00167	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GC—Graves' disease	5.03e-05	0.00163	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—B3GNT2—Graves' disease	4.55e-05	0.00147	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—B3GNT2—Graves' disease	3.81e-05	0.00123	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	3.58e-05	0.00116	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GC—Graves' disease	3.56e-05	0.00115	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GC—Graves' disease	2.85e-05	0.000921	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—B3GNT2—Graves' disease	2.7e-05	0.000874	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	2.54e-05	0.000822	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GC—Graves' disease	2.2e-05	0.000711	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—B3GNT2—Graves' disease	2.16e-05	0.000698	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HLA-A—Graves' disease	1.84e-05	0.000596	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—B3GNT2—Graves' disease	1.66e-05	0.000539	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CD4—Graves' disease	1.19e-05	0.000384	CbGpPWpGaD
